These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10558596)

  • 1. Entry decisions in the generic pharmaceutical industry.
    Morton FM
    Rand J Econ; 1999; 30(3):421-40. PubMed ID: 10558596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug patent expirations and the speed of generic entry.
    Bae JP
    Health Serv Res; 1997 Apr; 32(1):87-101. PubMed ID: 9108806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survey of developments in food and drug law from July 1998 to November 1999.
    Littlefield N; Hada NR
    Food Drug Law J; 2000; 55(1):35-56. PubMed ID: 12296348
    [No Abstract]   [Full Text] [Related]  

  • 4. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances.
    Danzon PM; Nicholson S; Pereira NS
    J Health Econ; 2005 Mar; 24(2):317-39. PubMed ID: 15721048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 7. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
    Kraushaar KJ
    Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
    [No Abstract]   [Full Text] [Related]  

  • 8. The Evolution of Supply and Demand in Markets for Generic Drugs.
    Frank RG; McGuire TG; Nason I
    Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the profit motive make Jack nimble? Ownership form and the evolution of the US hospital industry.
    Chakravarty S; Gaynor M; Klepper S; Vogt WB
    Health Econ; 2006 Apr; 15(4):345-61. PubMed ID: 16518796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical marketing in a new age. Effective campaigns still need to focus on what customers want.
    Rao SK
    Mark Health Serv; 2002; 22(1):6-12. PubMed ID: 11881547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 15. Authorized generic drugs, price competition, and consumers' welfare.
    Berndt ER; Mortimer R; Bhattacharjya A; Parece A; Tuttle E
    Health Aff (Millwood); 2007; 26(3):790-9. PubMed ID: 17485758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic drugs: the stalling game.
    Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multisource drugs: implications and concerns in the geriatric population.
    Gerbino PP; Joseph AS
    Hosp Pharm; 1993 Feb; 28(2):96-8, 101-2. PubMed ID: 10125706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community responses to national healthcare firms.
    Wholey DR; Christianson JB; Draper DA; Lesser CS; Burns LR
    J Health Soc Behav; 2004; 45 Suppl():118-35. PubMed ID: 15779470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Takings issues in the approval of generic biologics.
    Yoo JC
    Food Drug Law J; 2005; 60(1):33-43. PubMed ID: 15940853
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.